Monday, February 29, 2016

Allergan Gets FDA Acceptable For Filing Letter For Generic Xifaxan ANDA

Allergan plc (AGN) said it has received an Acceptable for Filing letter from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or ANDA seeking approval to market Rifaximin Tablets, 550 mg.

from RTT - Biotech http://ift.tt/1nbdCHX
via IFTTT

No comments:

Post a Comment